Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies

Keyphrases

• Tau Pathology 100%
• Alzheimer's Disease 100%
• Tauopathy 100%
• Acceptable Safety 100%
• Tau Antibodies 100%
• Humanized 100%
• Preclinical Development 100%
• Misfolding 100%
• Clinical Development 100%
• Progressive Supranuclear Palsy 100%
• Brain Regions 50%
• Cerebrospinal Fluid 50%
• Placebo 50%
• Placebo-controlled 50%
• Phase 1 Study 50%
• Adverse Events 50%
• Safety Profile 50%
• Early Alzheimer's Disease 50%
• Multiple Dose 50%
• Tolerability 50%
• Immunogenicity 50%
• Phase 1 Clinical Trial 50%
• Phase II Clinical Trial 50%
• Plasma Half-life 50%
• Transsynaptic 50%
• AbbVie 50%
• Tau Neurofibrillary Tangles 50%
• Pharmacokinetic Modeling 50%
• Humanized Antibody 50%
• Human tauopathies 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Alzheimer's Disease 100%
• Tauopathy 100%
• Placebo 66%
• Clinical Trial 66%
• Progressive Supranuclear Palsy 66%
• Adverse Event 33%
• Preclinical Study 33%
• Tolerability 33%
• Immunogenicity 33%
• Pharmacokinetic Modeling 33%
• Neurofibrillary Tangle 33%